TerminatedPhase 4

Acute Labetalol Use in Preeclampsia

Stopped: Slow enrollment

United States15 participantsStarted 2019-02-18

Plain-language summary

The purpose of this study is to understand if administration of a personalized dose of the anti-hypertensive medication, labetalol, based on patient's body-mass index, will be more effective at controlling severe hypertension during pregnancy, compared to the current standard dosing.

Who can participate

Age range18 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * BMI ≥ 30 * Age ≥ 18 years * Gestational age ≥ 24 weeks * Singleton gestation * One sustained severe range blood pressure at Albany Medical Center Exclusion Criteria: * Known allergic reaction to labetlol * Persistent mild-moderate asthma (≥ 2 rescue inhaler uses per week in the previous month) * Obstructive airway disease * Bradycardia \< 70 beats/min * Heart block \> 1st degree or history of heart failure

What they're measuring

Time to blood pressure control

Timeframe: 4 hours after last labetalol dosing

Trial details

NCT IDNCT03872336

SponsorAlbany Medical College

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2020-07-20

View on ClinicalTrials.gov More Preeclampsia With Severe Features trials